Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Methylprednisolone

Targets (1)Enzymes (1)Transporters (1)Biointeractions (4)

Identification

Name

Methylprednisolone

Accession Number

DB00959 (APRD00342)

Type

Small Molecule

Groups

Approved, Vet approved

Description

A prednisolone derivative with similar anti-inflammatory action.

Structure

Similar Structures

Synonyms

(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-dehydro-6α-methylhydrocortisone
6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
delta(1)-6alpha-Methylhydrocortisone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Metilprednisolona

External IDs

J3.872E / NSC-19987

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Methylprednisolone acetate	43502P7F0P	53-36-1	PLBHSZGDDKCEHR-LFYFAGGJSA-N

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Depo-Medrol	Injection, suspension	80 mg/1mL	Intralesional; Intramuscular; Intrasynovial; Soft tissue	Remedy Repack	2014-09-11	Not applicable
Depo-Medrol	Injection, suspension	40 mg/1mL	Intralesional; Intramuscular; Intrasynovial; Soft tissue	Pharmacia and Upjohn Company LLC	1959-05-28	Not applicable
Depo-Medrol	Injection, suspension	40 mg/1mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	Remedy Repack	2017-05-10	Not applicable
Depo-Medrol	Injection, suspension	80 mg/1mL	Intralesional; Intramuscular; Intrasynovial; Soft tissue	A-S Medication Solutions	1959-05-28	Not applicable
Depo-Medrol	Injection, suspension	40 mg/1mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	Physicians Total Care, Inc.	2005-05-03	2012-06-30
Depo-Medrol	Injection, suspension	40 mg/1mL	Intralesional; Intramuscular; Intrasynovial; Soft tissue	A-S Medication Solutions	1959-05-28	Not applicable
Depo-Medrol	Injection, suspension	40 mg/1mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	Cardinal Health	1959-05-28	Not applicable
Depo-Medrol	Injection, suspension	40 mg/1mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	A-S Medication Solutions	1959-05-28	Not applicable
Depo-Medrol	Injection, suspension	80 mg/1mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	Pharmacia and Upjohn Company LLC	1959-05-28	Not applicable
Depo-Medrol	Injection, suspension	40 mg/1mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	Remedy Repack	2016-06-15	2017-02-24

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
medPREDkit Plus	Kit	4 mg/1		Medarbor Llc	2018-01-24	2018-02-20
Methylprednisolone	Tablet	4 mg/1	Oral	A-S Medication Solutions	2018-05-01	Not applicable
Methylprednisolone	Tablet	4 mg/1	Oral	Unit Dose Services	1997-10-31	Not applicable
Methylprednisolone	Tablet	4 mg/1	Oral	Unit Dose Services	1997-10-31	Not applicable
Methylprednisolone	Tablet	4 mg/1	Oral	Rebel Distributors	1997-10-31	Not applicable
Methylprednisolone	Tablet	8 mg/1	Oral	Greenstone LLC	2013-03-25	Not applicable
Methylprednisolone	Tablet	16 mg/1	Oral	Jubilant Cadista Pharmaceuticals Inc.	1997-10-31	Not applicable
Methylprednisolone	Tablet	4 mg/1	Oral	Tianjin Tianyao Pharmaceuticals Co., Ltd.	2018-05-14	Not applicable
Methylprednisolone	Tablet	8 mg/1	Oral	Cadila Pharnmaceuticals	2018-05-01	Not applicable
Methylprednisolone	Tablet	4 mg/1	Oral	Physicians Total Care, Inc.	1994-11-29	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Depo-medrol With Lidocaine	Methylprednisolone acetate (40 mg) + Lidocaine hydrochloride (10 mg)	Solution	Intra-articular; Intrabursal	Pfizer	1973-12-31	Not applicable
Lido-mp40	Methylprednisolone acetate (40 mg/1mL) + Lidocaine hydrochloride (10 mg/1mL)	Kit	Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue	Burke Therapeutics, LLC	2015-06-18	2015-09-14
medPREDkit	Methylprednisolone (4 mg/1) + Omeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)	Kit		Medarbor Llc	2017-12-25	2018-01-15
Medrol Acne Lotion	Methylprednisolone acetate (2.5 mg) + Aluminum chlorohydrate (100 mg) + Octasulfur (50 mg)	Lotion	Topical	Pfizer	1973-12-31	2014-04-04
Methylprednisolone Sodium Succinate for Injection, USP	Methylprednisolone (500 mg) + Water (10 ml)	Powder, for solution	Intramuscular; Intravenous	Hospira, Inc.	1998-03-12	Not applicable
Methylprednisolone Sodium Succinate for Injection, USP	Methylprednisolone (1 g) + Water (20 ml)	Powder, for solution	Intramuscular; Intravenous	Hospira, Inc.	1998-03-12	Not applicable
Multi-Specialty Kit	Methylprednisolone acetate (40 mg/1mL) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL)	Kit		Proficient Rx LP	2014-02-06	Not applicable
Neo-medrol	Methylprednisolone acetate (2.5 mg) + Neomycin sulfate (5 mg)	Cream	Topical	Pfizer	1960-12-31	2006-08-02
Neo-medrol Acne Lotion	Methylprednisolone acetate (2.5 mg) + Aluminum chlorohydrate (100 mg) + Neomycin sulfate (2.5 mg) + Octasulfur (50 mg)	Lotion	Topical	Pfizer	1965-12-31	Not applicable
P-Care D40	Methylprednisolone acetate (40 mg/1mL) + Isopropyl Alcohol (0.7 mL/1mL) + Povidone-iodine (10 mg/1mL)	Kit		RX PHARMA-PACK, INC.	2017-06-16	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Dyural 40 Kit	Methylprednisolone acetate (40 mg/1mL) + Bupivacaine hydrochloride monohydrate (2.5 mg/1mL) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL) + Povidone-iodine (10 mg/1mL)	Kit	Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue; Subcutaneous; Topical	Asclemed Usa, Inc.	2014-07-25	Not applicable
Dyural 80 Kit	Methylprednisolone acetate (80 mg/1mL) + Bupivacaine hydrochloride monohydrate (2.5 mg/1mL) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL) + Povidone-iodine (10 mg/1mL)	Kit	Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue; Subcutaneous; Topical	Asclemed Usa, Inc.	2014-08-01	Not applicable
Dyural L Kit	Methylprednisolone acetate (40 mg/1mL) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL) + Povidone-iodine (10 mg/1mL)	Kit	Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue; Topical	Asclemed Usa, Inc.	2014-08-15	Not applicable
Dyural LM Kit	Methylprednisolone acetate (40 mg/1mL) + Bupivacaine hydrochloride monohydrate (2.5 mg/1mL) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL) + Povidone-iodine (10 mg/1mL)	Kit	Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue; Topical	Asclemed Usa, Inc.	2014-08-21	Not applicable
Hybrisil	Methylprednisolone acetate (10 mg/1g)	Gel	Topical	BioZone Laboratories, Inc.	2010-05-05	Not applicable
Medroloan II SUIK	Methylprednisolone acetate (40 mg/1mL)	Injection, suspension	Intra-articular; Intralesional; Intramuscular; Soft tissue	Asclemed Usa, Inc.	2016-06-29	Not applicable
Medroloan SUIK	Methylprednisolone acetate (40 mg/1mL)	Injection, suspension	Intra-articular; Intralesional; Intramuscular; Soft tissue	Asclemed Usa, Inc.	2016-06-29	Not applicable
Multi-Specialty Kit	Methylprednisolone acetate (40 mg/1mL) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL)	Kit	Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue; Topical	Asclemed Usa, Inc.	2014-02-06	Not applicable
Physicians EZ Use M-pred	Methylprednisolone acetate (40 mg/1mL) + Bupivacaine hydrochloride monohydrate (5 mg/1mL) + Povidone-iodine (10 mg/1g)	Kit	Epidural; Infiltration; Intramuscular; Intrasynovial; Soft tissue; Topical	Asclemed Usa, Inc.	2013-05-30	Not applicable

International/Other Brands

Medrate / Medrol / Medrone / Meprolone / Solomet / Urbason

Categories

UNII

X4W7ZR7023

CAS number

83-43-2

Weight

Average: 374.4706
Monoisotopic: 374.20932407

Chemical Formula

C₂₂H₃₀O₅

InChI Key

VHRSUDSXCMQTMA-PJHHCJLFSA-N

InChI

InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

IUPAC Name

(1R,3aS,3bS,5S,9aR,9bS,10S,11aS)-1,10-dihydroxy-1-(2-hydroxyacetyl)-5,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one

SMILES

[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C

Pharmacology

Indication

Adjunctive therapy for short-term administration in rheumatoid arthritis.

Associated Conditions

Pharmacodynamics

Methylprednisolone and its derivatives, methylprednisolone sodium succinate and methylprednisolone acetate, are synthetic glucocorticoids used as antiinflammatory or immunosuppressive agents.

Mechanism of action

Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

Target	Actions	Organism
AGlucocorticoid receptor	agonist	Human

Absorption

Oral bioavailability 80-99%

Volume of distribution

Not Available

Protein binding

78%

Metabolism

Hepatic

Route of elimination

Not Available

Half life

1-3 hours

Clearance

Not Available

Toxicity

LD₅₀=2000 mg/kg (orally in rat)

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction
(R)-warfarin	The metabolism of (R)-warfarin can be increased when combined with Methylprednisolone.
(S)-Warfarin	The metabolism of (S)-Warfarin can be increased when combined with Methylprednisolone.
1-Testosterone	The risk or severity of edema formation can be increased when 1-Testosterone is combined with Methylprednisolone.
1,10-Phenanthroline	The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Methylprednisolone.
16-Bromoepiandrosterone	The risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Methylprednisolone.
19-norandrostenedione	The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Methylprednisolone.
1alpha-Hydroxyvitamin D5	The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Methylprednisolone.
2-Methoxyethanol	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with 2-Methoxyethanol.
2,4-thiazolidinedione	The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Methylprednisolone.
3,5-diiodothyropropionic acid	The metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Methylprednisolone.

Food Interactions

Not Available

References

Synthesis Reference

Klaus Annen, Karl Petzoldt, Henry Laurent, Rudolf Wiechert, Helmut Hofmeister, "Novel 6.alpha.-methylprednisolone derivatives, their preparation, and their use." U.S. Patent US4587236, issued March, 1973.

US4587236

General References

Sloka JS, Stefanelli M: The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005 Aug;11(4):425-32. [PubMed:16042225]

External Links

Human Metabolome Database: HMDB0015094
KEGG Drug: D00407
PubChem Compound: 6741
PubChem Substance: 46504885
ChemSpider: 6485
BindingDB: 50103616
ChEBI: 6888
ChEMBL: CHEMBL650
Therapeutic Targets Database: DAP001040
PharmGKB: PA450466
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Methylprednisolone

ATC Codes

D07CA02 — Methylprednisolone and antibiotics

S01CA08 — Methylprednisolone and antiinfectives

D07AA01 — Methylprednisolone

D10AA02 — Methylprednisolone

H02AB04 — Methylprednisolone

H02BX01 — Methylprednisolone, combinations

AHFS Codes

68:04.00 — Adrenals
84:06.00 — Anti-inflammatory Agents

FDA label

Download (244 KB)

MSDS

Download (72.6 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Basic Science	Innate Immunity	1
0	Completed	Treatment	Chronic post-traumatic neuropathic pain in ankle and foot	1
0	Completed	Treatment	Friedreich's Ataxia	1
0	Recruiting	Treatment	Raynaud's Phenomenon / Sclerosis, Progressive Systemic	1
0	Terminated	Treatment	Complication of Anesthesia During Pregnancy, Unspecified / Fevers / Labour Pain	1
1	Active Not Recruiting	Treatment	Progressive Multiple Sclerosis	1
1	Completed	Basic Science	Biological Availability	1
1	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition	1
1	Completed	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Small Intestine Cancer	1
1	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
1	Completed	Treatment	Disseminated Sclerosis	2
1	Completed	Treatment	Drug Drug Interaction (DDI)	1
1	Completed	Treatment	Knee Osteoarthritis (Knee OA)	1
1	Completed	Treatment	Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Recruiting	Basic Science	Normal Physiology	1
1	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Untreated Adult Acute Myeloid Leukemia	1
1	Recruiting	Treatment	Congenital Hypoplastic Anemia	1
1	Recruiting	Treatment	Contiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia	1
1	Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Sickle Cell Disorders	1
1	Recruiting	Treatment	Multiple Myeloma (MM)	1
1	Recruiting	Treatment	Status Asthmaticus	1
1	Terminated	Not Available	Disseminated Sclerosis / Healthy Volunteers	1
1	Terminated	Treatment	Myasthenia Gravis	1
1	Terminated	Treatment	Myopathies	1
1	Terminated	Treatment	Rheumatoid Arthritis	1
1	Unknown Status	Supportive Care	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
1	Unknown Status	Treatment	Leukemias / Myelodysplastic Syndromes	1
1	Unknown Status	Treatment	Malignant Lymphomas	1
1	Unknown Status	Treatment	Neuromyelitis Optica	1
1	Unknown Status	Treatment	Ocular GVHD	1
1	Unknown Status	Treatment	Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Withdrawn	Basic Science	Therapeutic Equivalency	3
1, 2	Active Not Recruiting	Treatment	Classical Hodgkin Lymphoma	1
1, 2	Active Not Recruiting	Treatment	Drug-Induced Liver Injury, Chronic	1
1, 2	Active Not Recruiting	Treatment	Neuromyelitis Optica	1
1, 2	Completed	Prevention	Ovarian Hyperstimulation Syndrome	1
1, 2	Completed	Treatment	Acute Lymphocytic Leukemia (ALL) / Leukemias	1
1, 2	Completed	Treatment	Congenital Hypoplastic Anemia	1
1, 2	Completed	Treatment	Inhospital Cardiac Arrest	1
1, 2	Completed	Treatment	Kidney Diseases / Transplantation, Kidney	1
1, 2	Completed	Treatment	Leukemias	1
1, 2	Completed	Treatment	Spinal Cord Injuries (SCI)	2
1, 2	Completed	Treatment	Systemic Lupus Erythematosus (SLE)	1
1, 2	Completed	Treatment	Traumatic Optic Neuropathy	1
1, 2	Not Yet Recruiting	Treatment	Acute Graft-Versus-Host Disease	1
1, 2	Recruiting	Prevention	Cognitive Retention Disorder / Postoperative Complications	1
1, 2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myeloid Leukemia (CML) / Juvenile Myelomonocytic Leukemia (JMML) / Lymphoma (Hodgkin's and Non-Hodgkin's) / Myelodysplastic Syndromes (MDS)	1
1, 2	Recruiting	Treatment	Congenital Hypoplastic Anemia	1
1, 2	Recruiting	Treatment	Disseminated Sclerosis	1
1, 2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndrome	1
1, 2	Terminated	Treatment	Leukemias	1
1, 2	Terminated	Treatment	Leukemias / Myeloproliferative Disorders / Plasma Cell Myeloma	1
1, 2	Unknown Status	Not Available	Atherosclerosis	1
1, 2	Withdrawn	Prevention	Noise Induced Hearing Loss	1
2	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia	1
2	Active Not Recruiting	Treatment	Anaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)	2
2	Active Not Recruiting	Treatment	Leukemias	2
2	Active Not Recruiting	Treatment	Lymphoproliferative Disorders	1
2	Active Not Recruiting	Treatment	Malignant Lymphomas	1
2	Active Not Recruiting	Treatment	Nephritis, Lupus	2
2	Active Not Recruiting	Treatment	Relapsing Remitting Multiple Sclerosis (RRMS)	1
2	Active Not Recruiting	Treatment	Transplantation, Kidney	1
2	Completed	Diagnostic	Malignant Lymphomas	1
2	Completed	Prevention	Hyperalgesia / Knee Joint Osteoarthrosis / Severe Movement Related Pain	1
2	Completed	Supportive Care	Cancer of the Ovary / Cancer, Breast / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Neuroblastomas / Testicular germ cell tumour	2
2	Completed	Supportive Care	Malignancies	1
2	Completed	Supportive Care	Malignant Lymphomas / Neutropenias	1
2	Completed	Treatment	Abdominal wall neoplasm / Carcinomatosis / Intestinal Obstruction	1
2	Completed	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Promyelocytic Leukemia (M3) / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)	1
2	Completed	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Disseminated Neuroblastoma / Juvenile Myelomonocytic Leukemia / Previously Treated Childhood Rhabdomyosarcoma / Previously Treated Myelodysplastic Syndromes / Pulmonary Complications / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Neuroblastoma / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Recurrent/Refractory Childhood Hodgkin Lymphoma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Secondary Myelodysplastic Syndromes	1
2	Completed	Treatment	Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Postoperative Complications	1
2	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemias	1
2	Completed	Treatment	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Splenic Marginal Zone Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Waldenström's Macroglobulinemia (WM)	1
2	Completed	Treatment	Adverse Effect of Radiation Therapy / Brain Necrosis / Nasopharyngeal Carcinoma	1
2	Completed	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
2	Completed	Treatment	Aplastic Anaemia (AA)	1
2	Completed	Treatment	Aplastic Anaemia (AA) / Myelodysplastic Syndrome	1
2	Completed	Treatment	Blood Cancers / Chronic Lymphocytic Leukaemia (CLL) / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Leukemias / Malignancies / NHL / Smith-Magenis Syndrome	1
2	Completed	Treatment	Bursitis	1
2	Completed	Treatment	Cancer of the Ovary / Cancer, Breast / Fallopian Tube Cancer / Primary Peritoneal Cancer	1
2	Completed	Treatment	Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Chronic B-Lymphocytic Leukemia	1
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Chronic Renal Failure (CRF) / Transplantation, Kidney	1
2	Completed	Treatment	Congenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Leukemias / Myelodysplastic Syndromes / Severe Congenital Neutropenia	1
2	Completed	Treatment	Connective Tissue Diseases / Dermatomyositis / Vasculitis / Vasculitis, Hypersensitivity	1
2	Completed	Treatment	Giant Cell Myocarditis / Myocarditis	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD)	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Neuroblastomas	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Thymic Carcinoma	1
2	Completed	Treatment	Granulomatosis With Polyangiitis / Microscopic Polyangiitis / Renal Limited Vasculitis	1
2	Completed	Treatment	Hantavirus Infections	1
2	Completed	Treatment	Hormone Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer	1
2	Completed	Treatment	Leukemia, Mast-Cell / Mantle Cell Lymphoma (MCL)	1
2	Completed	Treatment	Leukemias	3
2	Completed	Treatment	Leukemias / Malignant Lymphomas	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic-Myeloproliferative Diseases	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
2	Completed	Treatment	Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Completed	Treatment	Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Lupus Erythematosus, Systemic	1
2	Completed	Treatment	Malignant Lymphomas	2
2	Completed	Treatment	Multiple Myeloma (MM)	1
2	Completed	Treatment	Nephritis, Lupus	1
2	Completed	Treatment	Progressive Multiple Sclerosis	1
2	Completed	Treatment	Rejection, Transplant	1
2	Completed	Treatment	Relapsing Remitting Multiple Sclerosis (RRMS)	1
2	Completed	Treatment	Rheumatoid Arthritis	2
2	Completed	Treatment	Suspected Appendicitis	1
2	Enrolling by Invitation	Treatment	Disseminated Sclerosis	1
2	Enrolling by Invitation	Treatment	Graft Versus Host Disease (GVHD)	1
2	Not Yet Recruiting	Prevention	Acute GvHD	1
2	Not Yet Recruiting	Treatment	Acute-graft-versus-host Disease	1
2	Not Yet Recruiting	Treatment	Antibody-mediated Rejection / Lung Transplant Rejection	1
2	Not Yet Recruiting	Treatment	Caustic Esophageal Injury / Esophageal Strictures / Pharyngeal stenosis	1
2	Not Yet Recruiting	Treatment	High Cholesterol / Thyroid Associated Ophthalmopathy	1
2	Not Yet Recruiting	Treatment	Immune Thrombocytopenia	1
2	Not Yet Recruiting	Treatment	Systemic Lupus Erythematosus Arthritis	1
2	Recruiting	Treatment	Aplastic Anaemia (AA) / Hypoplastic Myelodysplastic Syndrome	1
2	Recruiting	Treatment	Cerebral Radiation Necrosis	1
2	Recruiting	Treatment	Congenital Hypoplastic Anemia	1
2	Recruiting	Treatment	Crohn's Disease (CD)	1
2	Recruiting	Treatment	Disseminated Sclerosis	1
2	Recruiting	Treatment	Graft Versus Host Disease (GVHD)	1
2	Recruiting	Treatment	Graft Versus Host Disease, Acute	1
2	Recruiting	Treatment	Henoch-Schoenlein Purpura Nephritis	1
2	Recruiting	Treatment	IgA Glomerulonephritis / Necrosis / Peripapillary Crescent / Steroid Nephropathy	1
2	Recruiting	Treatment	Leukemias	2
2	Recruiting	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	1
2	Recruiting	Treatment	Multiple Myeloma (MM)	1
2	Recruiting	Treatment	Multiple Sclerosis, Chronic Progressive / Nervous System Diseases	1
2	Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
2	Recruiting	Treatment	Systemic Lupus Erythematosus Arthritis	1
2	Recruiting	Treatment	Transplant, Kidney	1
2	Terminated	Not Available	Acute Exacerbation of Remitting Relapsing Multiple Sclerosis / Clinically Isolated Syndrome (CIS)	1
2	Terminated	Treatment	Blood and Marrow Transplant (BMT) / Diffuse Large B-Cell / Lymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphomas: Non-Hodgkin / Malignant Lymphoma, Non-Hodgkin / Non-Hodgkin's Lymphoma (NHL)	1
2	Terminated	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Terminated	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Terminated	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood	1
2	Terminated	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases	1
2	Terminated	Treatment	End-Stage Renal Disease (ESRD)	1
2	Terminated	Treatment	Graves Ophthalmopathy	1
2	Terminated	Treatment	Haematological Malignancies	1
2	Terminated	Treatment	Insufficiency; Hepatic, Postoperative / Ischemic Reperfusion Injury / Neoplasms, Hepatic	1
2	Terminated	Treatment	Leukemias	1
2	Terminated	Treatment	Leukemias / Myelodysplastic Syndromes	1
2	Terminated	Treatment	Malignant Lymphomas	1
2	Terminated	Treatment	Non-Hodgkin's Lymphoma (NHL)	2
2	Terminated	Treatment	Pelvic Girdle Pain	1
2	Terminated	Treatment	Polyp of Nasal Sinus	1
2	Terminated	Treatment	Primary Renal Allograft Candidate / Transplantation, Kidney	1
2	Terminated	Treatment	Primary Simultaneous Kidney and Pancreas Allograft Candidates / Simultaneous Kidney and Pancreas Transplantation	1
2	Terminated	Treatment	Rheumatoid Arthritis	3
2	Terminated	Treatment	Spondylarthropathy	1
2	Terminated	Treatment	Transplant, Kidney	1
2	Terminated	Treatment	Transplantation, Kidney	1
2	Terminated	Treatment	Transplantation, Kidney / Transplantation, Renal	1
2	Unknown Status	Treatment	Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS)	1
2	Unknown Status	Treatment	Ankylosing Spondylitis (AS)	1
2	Unknown Status	Treatment	Childhood Langerhans Cell Histiocytosis / Congenital Hypoplastic Anemia / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific	1
2	Unknown Status	Treatment	Early and Severe Systemic Sclerosis	1
2	Unknown Status	Treatment	Elective Cardiac Surgery	1
2	Unknown Status	Treatment	Leukemias	1
2	Unknown Status	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Unknown Status	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
2	Unknown Status	Treatment	Malignant Lymphomas	1
2	Unknown Status	Treatment	Primary Central Nervous System Lymphoma (PCNSL)	1
2	Withdrawn	Treatment	Adult Non-Hodgkin's Lymphoma / Anaplastic Large Cell Lymphoma / Lymphoma, AIDS Related	1
2	Withdrawn	Treatment	Chronic Graft Versus Host Disease	1
2	Withdrawn	Treatment	Disseminated Sclerosis	1
2	Withdrawn	Treatment	Graft Versus Host Disease, Acute / Intestinal Graft Versus Host Disease	1
2	Withdrawn	Treatment	Lung Cancers / Melanoma / Renal Cell Adenocarcinoma	1
2	Withdrawn	Treatment	Plasma Cell Myeloma	1
2	Withdrawn	Treatment	Systemic Lupus Erythematosus (SLE)	1
2, 3	Active Not Recruiting	Treatment	Childhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma	1
2, 3	Completed	Not Available	Degenerative Joint Disease	2
2, 3	Completed	Treatment	Acute Alcoholic Hepatitis	1
2, 3	Completed	Treatment	Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
2, 3	Completed	Treatment	Aplastic Anaemia (AA) / Dyskeratosis Congenita	1
2, 3	Completed	Treatment	Carpal Tunnel Syndrome (CTS)	1
2, 3	Completed	Treatment	Familial Lipoprotein Lipase Deficiency	1
2, 3	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes	1
2, 3	Completed	Treatment	Granulomatosis With Polyangiitis / Microscopic Polyangiitis / Vasculitis	1
2, 3	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes	1
2, 3	Completed	Treatment	Lumbosacral Radiculopathy	1
2, 3	Completed	Treatment	Menière's Disease	1
2, 3	Completed	Treatment	Ophthalmopathy, Thyroid-Associated	1
2, 3	Completed	Treatment	Optic Neuritis	1
2, 3	Completed	Treatment	Sinusitis	1
2, 3	Not Yet Recruiting	Treatment	Thyroid Eye Disease	1
2, 3	Recruiting	Prevention	Complications	1
2, 3	Recruiting	Treatment	Acute Gouty Arthritis / Chronic Kidney Disease (CKD)	1
2, 3	Recruiting	Treatment	Diabetes Complications / Neuropathic arthropathy	1
2, 3	Recruiting	Treatment	Heart Arrest	1
2, 3	Recruiting	Treatment	Leukemias	1
2, 3	Recruiting	Treatment	Scleroderma / Sclerosis, Progressive Systemic	1
2, 3	Terminated	Treatment	Disseminated Sclerosis	1
2, 3	Terminated	Treatment	Lupus Erythematosus, Systemic	1
2, 3	Unknown Status	Treatment	Acute Lung Injury (ALI) / ARDS, Human	1
3	Active Not Recruiting	Prevention	Dysphasia	1
3	Active Not Recruiting	Prevention	Swallowing Disorders	1
3	Active Not Recruiting	Treatment	Cardiopulmonary Bypass	1
3	Active Not Recruiting	Treatment	Drug/Agent Toxicity by Tissue/Organ / Leukemias	1
3	Completed	Not Available	Degenerative Joint Disease	4
3	Completed	Prevention	Facial Paralysis	1
3	Completed	Prevention	Kidney Diseases	1
3	Completed	Prevention	Post-Extubation Laryngeal Edema	1
3	Completed	Prevention	Transplantation, Kidney	1
3	Completed	Supportive Care	Graft Versus Host Disease (GVHD)	1
3	Completed	Supportive Care	Graft Versus Host Disease (GVHD) / Recurrent Adult Acute Lymphoblastic Leukemia	1
3	Completed	Supportive Care	Malignancies / Pain NOS	1
3	Completed	Treatment	Abdominal Pain (AP)	1
3	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Undifferentiated Leukemia (AUL) / Childhood T Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Completed	Treatment	Cardiac Arrest	1
3	Completed	Treatment	Chronic Kidney Disease (CKD) / IgA Nephropathy	1
3	Completed	Treatment	Chronic Lung Disease of Prematurity	1
3	Completed	Treatment	Chronic Lung Diseases / Respiratory Distress Syndrome, Adult	1
3	Completed	Treatment	Community Acquired Respiratory Disease Syndrome	1
3	Completed	Treatment	Dexamethasone-induced Hiccup in Chemotherapy	1
3	Completed	Treatment	Graft Versus Host Disease (GVHD)	1
3	Completed	Treatment	Heart Diseases / Heart Transplantation	1
3	Completed	Treatment	Hemangiomas	1
3	Completed	Treatment	Idiopathic Pneumonia Syndrome / Pneumonia	1
3	Completed	Treatment	Immune Thrombocytopenic Purpura ( ITP )	1
3	Completed	Treatment	Leukemias	1
3	Completed	Treatment	Malignant Lymphomas	3
3	Completed	Treatment	Multiple Sclerosis, Chronic Progressive	1
3	Completed	Treatment	Nephritis, Lupus	1
3	Completed	Treatment	Radicular Low Back Pain	1
3	Completed	Treatment	Rheumatoid Arthritis	4
3	Completed	Treatment	Spinal Cord Injuries (SCI)	1
3	Completed	Treatment	Sudden Deafness	1
3	Completed	Treatment	Transplant; Failure, Kidney	1
3	Completed	Treatment	Transplantation, Kidney	3
3	Not Yet Recruiting	Treatment	Arterial Ischemic Stroke	1
3	Not Yet Recruiting	Treatment	Chronic Graft Versus Host Disease	1
3	Not Yet Recruiting	Treatment	Persistent ARDS	1
3	Not Yet Recruiting	Treatment	Prostate Cancer	1
3	Recruiting	Prevention	Herniated Nucleus Pulposus / Intervertebral Disc Degeneration / Myelopathy / Myeloradiculopathy / Radicular syndrome / Spondylosis / Stenosis	1
3	Recruiting	Treatment	Acute Graft-Versus-Host Disease / Graft-versus-host Disease (GVHD)	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Aging	1
3	Recruiting	Treatment	Chronic Subdural Hematomas	1
3	Recruiting	Treatment	Congenital Heart Disease in Children / Inflammatory Responses	1
3	Recruiting	Treatment	Disseminated Sclerosis	1
3	Recruiting	Treatment	Dry Eye Syndrome (DES) / Ophthalmopathy, Thyroid-Associated	1
3	Recruiting	Treatment	Glomerulonephritis membranous	1
3	Recruiting	Treatment	Glomerulonephritis, Membranous	1
3	Recruiting	Treatment	Glucocorticoid therapy / Immunocompromised Patients / Immunosuppressive Agents / Neoplasms / Neoplasms, Hematologic / Pneumocystis	1
3	Recruiting	Treatment	Lymphohistiocytosis, Hemophagocytic	2
3	Recruiting	Treatment	Relapsing Remitting Multiple Sclerosis (RRMS)	1
3	Recruiting	Treatment	Thrombocytopenias	1
3	Suspended	Treatment	Spinal Cord Injuries (SCI)	1
3	Terminated	Treatment	Disseminated Sclerosis	1
3	Terminated	Treatment	Evidence of Liver Transplantation / Transplantations	1
3	Terminated	Treatment	Glomerulonephritis	1
3	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii	1
3	Terminated	Treatment	Malignant Lymphomas	1
3	Terminated	Treatment	Neuromyelitis Optica / Transverse Myelitis	1
3	Terminated	Treatment	Prostate Cancer	1
3	Terminated	Treatment	Systemic Lupus Erythematosus (SLE)	1
3	Unknown Status	Treatment	Chronic Lymphocytic Leukaemia (CLL)	1
3	Unknown Status	Treatment	Disseminated Sclerosis / Optic Neuritis	1
3	Unknown Status	Treatment	Leukemias / Malignant Lymphomas	1
3	Unknown Status	Treatment	Malignant Lymphomas	1
3	Unknown Status	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
3	Unknown Status	Treatment	NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)	1
3	Unknown Status	Treatment	Osteoarthritis (OA)	1
3	Unknown Status	Treatment	Relapsing Remitting Multiple Sclerosis (RRMS)	1
3	Unknown Status	Treatment	Urinary Tract Infections (UTIs)	1
3	Unknown Status	Treatment	Vestibular Neuritis	1
3	Withdrawn	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas	1
3	Withdrawn	Treatment	Human Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii	1
4	Active Not Recruiting	Prevention	Infections, Cytomegalovirus / Transplantation Infection	1
4	Active Not Recruiting	Prevention	Postoperative Complications	1
4	Active Not Recruiting	Treatment	Plantar fascial fibromatosis	1
4	Completed	Not Available	Healthy Volunteers	1
4	Completed	Not Available	Relapsing Remitting Multiple Sclerosis (RRMS)	1
4	Completed	Prevention	Adrenocortical Deficiency / Hemodynamics Instability	1
4	Completed	Prevention	Delirium - Postoperative / Stress, Physiological	1
4	Completed	Prevention	Esophageal Diseases	1
4	Completed	Prevention	Hysterectomy / Methylprednisolone / Postoperative pain	1
4	Completed	Prevention	Migraines	1
4	Completed	Prevention	Transplantation, Kidney	2
4	Completed	Prevention	Transplantation, Liver	1
4	Completed	Supportive Care	Inflammatory Responses / LOS / Post-Operative Nausea and Vomiting (PONV) / Postoperative pain / Sleeping Quality / Tiredness	1
4	Completed	Supportive Care	Inflammatory Responses / Post-Operative Nausea and Vomiting (PONV) / Postoperative pain / Sleeping Quality / Tiredness	1
4	Completed	Treatment	Acute Respiratory Distress Syndrome (ARDS)	1
4	Completed	Treatment	Adrenal Insufficiency / Tendinopathy	1
4	Completed	Treatment	Alopecia Totalis (AT) / Alopecia Universalis (AU) / Ophiasic Alopecia	1
4	Completed	Treatment	Asthma Acute / Asthma Bronchial / Reactive Airway Exacerbation	1
4	Completed	Treatment	Asthma Bronchial	1
4	Completed	Treatment	Atopic Dermatitis (AD)	1
4	Completed	Treatment	Calcifying Tendinitis of Shoulder	1
4	Completed	Treatment	Carpal Tunnel Syndrome (CTS)	1
4	Completed	Treatment	Children / Chronic Rhinosinusitis	1
4	Completed	Treatment	Community Acquired Pneumonia (CAP)	1
4	Completed	Treatment	Crohn's Disease (CD)	1
4	Completed	Treatment	Disseminated Sclerosis	1
4	Completed	Treatment	HLA Sensitization	1
4	Completed	Treatment	Heart Transplantation	1
4	Completed	Treatment	Implant or Graft; Rejection	1
4	Completed	Treatment	Knee Osteoarthritis (Knee OA)	1
4	Completed	Treatment	Liver Cirrhosis / Liver Transplant Disorder	1
4	Completed	Treatment	Migrainous Headache	1
4	Completed	Treatment	Neoplasms, Lung	1
4	Completed	Treatment	Nephritis, Lupus	1
4	Completed	Treatment	Osteoarthritis (OA)	2
4	Completed	Treatment	Plantar fascial fibromatosis	1
4	Completed	Treatment	Rejection, Transplant / Renal Failure / Transplantation, Kidney	1
4	Completed	Treatment	Relapsing Remitting Multiple Sclerosis (RRMS)	3
4	Completed	Treatment	Rheumatoid Arthritis	5
4	Completed	Treatment	Sarcopenia	1
4	Completed	Treatment	Sciatica	1
4	Completed	Treatment	Sepsis	1
4	Completed	Treatment	Arthralgia/joint pain / TMJ	1
4	Completed	Treatment	Transplantation, Kidney	1
4	Completed	Treatment	Transplantation, Liver	1
4	Completed	Treatment	Viral Bronchiolitis	1
4	Completed	Treatment	Acute fulminant liver failure	1
4	Enrolling by Invitation	Treatment	Osteoarthritis (OA)	1
4	Not Yet Recruiting	Prevention	Graves Ophthalmopathy	1
4	Not Yet Recruiting	Prevention	Post-Craniotomy Headache / Postoperative pain	1
4	Not Yet Recruiting	Treatment	Acromioclavicular Joint Resection / Acromioplasty / Arthroscopic Shoulder Surgery / Intra-articular Debridement / Subacromial Decompression	1
4	Not Yet Recruiting	Treatment	Thyroid Associated Ophthalmopathy	1
4	Recruiting	Other	Ulcerative Colitis (UC)	1
4	Recruiting	Prevention	End-Stage Renal Disease (ESRD)	1
4	Recruiting	Treatment	Adhesive Capsulitis / Adhesive Capsulitis of Shoulder / Shoulder Frozen	1
4	Recruiting	Treatment	C.Surgical Procedure / Cardiac	1
4	Recruiting	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
4	Recruiting	Treatment	Community Acquired Pneumonia (CAP)	1
4	Recruiting	Treatment	Crohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)	1
4	Recruiting	Treatment	Disseminated Sclerosis	2
4	Recruiting	Treatment	Drug Interaction Potentiation / Transplantation, Kidney	1
4	Recruiting	Treatment	Immunosuppression	1
4	Recruiting	Treatment	Knee Osteoarthritis (Knee OA)	1
4	Recruiting	Treatment	Orthopedic Surgeries	1
4	Recruiting	Treatment	Post-operative Edema / Steroid Use	1
4	Recruiting	Treatment	Thyroid Associated Ophthalmopathy	1
4	Recruiting	Treatment	Ulcerative Colitis (UC)	1
4	Recruiting	Treatment	Acute nonspecific tenosynovitis	1
4	Suspended	Treatment	Wegener's Granulomatosis or Microscopic Polyangiitis / Wegener's Granulomatosis, Microscopic Polyangiitis	1
4	Terminated	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
4	Terminated	Treatment	Immune Reconstitution Inflammatory Syndrome / Progressive Multifocal Leukoencephalopathy	1
4	Terminated	Treatment	Transplants and Implants	1
4	Unknown Status	Treatment	Behcet's Syndrome	1
4	Unknown Status	Treatment	Cardiac Surgical Procedures / Cardiopulmonary Bypass / Systemic Inflammatory Response Syndrome (SIRS)	1
4	Unknown Status	Treatment	Endocrine ophthalmopathy	1
4	Unknown Status	Treatment	Mastectomy / Neoplasms, Breast	1
4	Unknown Status	Treatment	Transplantation, Renal	1
4	Withdrawn	Not Available	Asthma Bronchial	1
4	Withdrawn	Treatment	Demyelinating Disorders / Disseminated Sclerosis / Myelitis NOS / Neuritis / Optic Neuritis	1
4	Withdrawn	Treatment	Pediatric Crohn's Disease	1
Not Available	Active Not Recruiting	Treatment	Congenital Heart Disease (CHD) / Disorder of Fetus or Newborn	1
Not Available	Completed	Not Available	Autoimmune Encephalitis / Cognitive Impairments	1
Not Available	Completed	Not Available	Blood Pressures / Graves Diseases / Graves Ophthalmopathy / Heart Failure, Unspecified / High Blood Pressure (Hypertension)	1
Not Available	Completed	Not Available	Coagulation, Blood / Graves Ophthalmopathy / Graves' Disease / Venous Thromboembolism (VTE)	1
Not Available	Completed	Not Available	Corticosteroid Injection / Shoulder Pain / Type2 Diabetes Mellitus	1
Not Available	Completed	Not Available	Dermatitis, Contact	1
Not Available	Completed	Prevention	Heart Valve Diseases / Systemic Inflammatory Response Syndrome (SIRS)	1
Not Available	Completed	Supportive Care	Inflammatory Reaction / Postoperative pain	1
Not Available	Completed	Supportive Care	Osteoarthritis (OA)	1
Not Available	Completed	Supportive Care	Osteoarthritis (OA) / Post-traumatic; Arthrosis	1
Not Available	Completed	Treatment	Abdominal Aortic Aneurysms (AAA)	1
Not Available	Completed	Treatment	Aortic Valve Stenosis	1
Not Available	Completed	Treatment	Back Pain Lower Back Chronic	1
Not Available	Completed	Treatment	Biliary Atresia	1
Not Available	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
Not Available	Completed	Treatment	Congenital Heart Disease (CHD) / Disorder of Fetus or Newborn	1
Not Available	Completed	Treatment	Disc Disease	1
Not Available	Completed	Treatment	Edema / Pain NOS / Trismus	1
Not Available	Completed	Treatment	End-Stage Renal Disease (ESRD)	1
Not Available	Completed	Treatment	Hand, Foot, and Mouth Disease	1
Not Available	Completed	Treatment	Leukemias	1
Not Available	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific	1
Not Available	Completed	Treatment	Pain, Chronic	1
Not Available	Completed	Treatment	Shoulder Pain / Subacromial Bursitis	1
Not Available	Completed	Treatment	Transplantation, Kidney	1
Not Available	Enrolling by Invitation	Prevention	Cervical Degenerative Disc Disease / Cervical Disc Herniation / Cervical Spondylotic Myelopathy / Osteoarthritis of Cervical Spine / Swallowing Disorders	1
Not Available	Not Yet Recruiting	Prevention	Aortic Dissection	1
Not Available	Not Yet Recruiting	Treatment	Alcoholic Hepatitis (AH)	1
Not Available	Not Yet Recruiting	Treatment	Henoch-Schönlein Purpura	1
Not Available	Recruiting	Not Available	Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / Gynaecological infection / Headaches / Herpes Simplex Virus / High Blood Pressure (Hypertension) / High Cholesterol / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain NOS / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombotic events / Toxic effect of hydrocyanic acid and cyanides / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal	1
Not Available	Recruiting	Not Available	Acute Exacerbation of Chronic Obstructive Pulmonary Disease / Alveolar Hypoventilation / Chronic Obstructive Pulmonary Disease (COPD) / Copd Exacerbation Acute / Emphysema or COPD / Respiratory Failure	1
Not Available	Recruiting	Not Available	Asthma Bronchial	1
Not Available	Recruiting	Not Available	Chronic Renal Failure (CRF)	1
Not Available	Recruiting	Not Available	Graves Ophthalmopathy	1
Not Available	Recruiting	Treatment	Biceps Tendonitis / Injections	1
Not Available	Recruiting	Treatment	Carpal Tunnel Syndrome (CTS) / Pain, Chronic / Scleroderma	1
Not Available	Recruiting	Treatment	Childhood Acute Lymphoblastic Leukemia	1
Not Available	Recruiting	Treatment	Chronic Renal Failure (CRF)	1
Not Available	Recruiting	Treatment	Disorder Related to Renal Transplantation / Effects of Immunosuppressant Therapy	1
Not Available	Recruiting	Treatment	IgA Glomerulonephritis	1
Not Available	Recruiting	Treatment	Immunosuppression	1
Not Available	Recruiting	Treatment	Knee Arthropathy	1
Not Available	Recruiting	Treatment	Mycoplasma Pneumoniae Pneumonia	1
Not Available	Recruiting	Treatment	Neuroma, Human Forefoot	1
Not Available	Recruiting	Treatment	Osteoarthritis of the Glenohumeral Joint	1
Not Available	Recruiting	Treatment	Pneumonia, Pneumocystis	1
Not Available	Recruiting	Treatment	Systemic Lupus Erythematosus (SLE)	1
Not Available	Recruiting	Treatment	Traumatic Optic Neuropathy	1
Not Available	Recruiting	Treatment	Ventral Hernias	1
Not Available	Terminated	Other	Lumbar Back Pain / Lumbar Radiculitis / Lumbar Spine Disc Herniation	1
Not Available	Terminated	Treatment	Acute Respiratory Distress Syndrome (ARDS)	1
Not Available	Terminated	Treatment	Bruton's agammaglobulinemia / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Immunologic Deficiency Syndromes / Leukocyte Adhesion Deficiency Syndrome / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Virus-Associated Hemophagocytic Syndrome / Wiskott-Aldrich Syndrome (WAS) / X-Linked Hyper IgM Syndrome / X-Linked Lymphoproliferative Syndrome	1
Not Available	Terminated	Treatment	Chronic Myeloproliferative Disorders / Congenital Hypoplastic Anemia / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
Not Available	Terminated	Treatment	Disseminated Sclerosis	1
Not Available	Terminated	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
Not Available	Terminated	Treatment	Graft Versus Host Disease, Acute	1
Not Available	Terminated	Treatment	Inflammatory Bowel Diseases (IBD)	1
Not Available	Terminated	Treatment	Refractory Mycoplasma Pneumoniae Pneumonia	1
Not Available	Terminated	Treatment	Shoulder Impingement Syndrome	1
Not Available	Unknown Status	Prevention	Leukemias	1
Not Available	Unknown Status	Treatment	Anemia, Hemolytic, Autoimmune / Autoimmune Thrombocytopenic Purpura / Churg-Strauss Syndrome (CSS) / Giant Cells Arteritis / Graft Versus Host Disease (GVHD) / Granulomatosis With Polyangiitis / Polyarteritis Nodosa / Pure Red Cell Aplasia / Purpura, Schoenlein-Henoch / Rheumatoid Arthritis / Rheumatoid Arthritis, Juvenile / Systemic Lupus Erythematosus (SLE) / Takayasu's Disease / Vasculitis, Hypersensitivity	1
Not Available	Unknown Status	Treatment	Aplastic Anaemia (AA) / Graft Versus Host Disease (GVHD)	1
Not Available	Unknown Status	Treatment	Carpal Tunnel Syndrome (CTS)	1
Not Available	Unknown Status	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	2
Not Available	Unknown Status	Treatment	Disseminated Sclerosis / Optic Neuritis	1
Not Available	Unknown Status	Treatment	Knee Osteoarthritis (Knee OA)	1
Not Available	Unknown Status	Treatment	Severe Acute Exacerbation of Chronic Hepatitis B	1
Not Available	Withdrawn	Diagnostic	Lung Cancers	1
Not Available	Withdrawn	Treatment	Bronchiolitis	1
Not Available	Withdrawn	Treatment	Dexamethasone / Hiccups	1

Pharmacoeconomics

Manufacturers

Pharmacia and upjohn co
Cadista pharmaceuticals inc
Duramed pharmaceuticals inc sub barr laboratories inc
Heather drug co inc
Par pharmaceutical inc
Sandoz inc
Vintage pharmaceuticals inc
Watson laboratories inc
Abbott laboratories hosp products div
Hemopharm usa corp
Hospira inc
Elkins sinn div ah robins co inc
Organon usa inc
Abraxis pharmaceutical products
App pharmaceuticals llc
Bedford laboratories
International medication systems ltd
Teva parenteral medicines inc

Packagers

Advanced Pharmaceutical Services Inc.
Aidarex Pharmacuticals LLC
Amerisource Health Services Corp.
Apotheca Inc.
APP Pharmaceuticals
A-S Medication Solutions LLC
Barr Pharmaceuticals
Bedford Labs
Breckenridge Pharmaceuticals
Bryant Ranch Prepack
C.O. Truxton Inc.
Cadista Pharmaceuticals Inc.
Cardinal Health
Carlisle Laboratories Inc.
Clint Pharmaceutical Inc.
DAVA Pharmaceuticals
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
DRX Pharmaceuticals
General Injectables and Vaccines Inc.
Greenstone LLC
H.J. Harkins Co. Inc.
Hemofarm AD
Hospira Inc.
Innoviant Pharmacy Inc.
Keltman Pharmaceuticals Inc.
Major Pharmaceuticals
Mckesson Corp.
Medisca Inc.
Merrell Pharmaceuticals Inc.
Neuman Distributors Inc.
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
Par Pharmaceuticals
Patheon Inc.
PD-Rx Pharmaceuticals Inc.
Pfizer Inc.
Pharmacia Inc.
Pharmedix
Physician Partners Ltd.
Physicians Total Care Inc.
Prasco Labs
Preferred Pharmaceuticals Inc.
Prescript Pharmaceuticals
Qualitest
Rebel Distributors Corp.
Redpharm Drug
San Jose Surgical Supply Inc.
Sandhills Packaging Inc.
Sandoz
Schein Pharmaceutical Inc.
Sicor Pharmaceuticals
Southwood Pharmaceuticals
Spectrum Pharmaceuticals
Stat Rx Usa
Vintage Pharmaceuticals Inc.

Dosage forms

Form	Route	Strength
Injection, suspension	Intralesional; Intramuscular; Intrasynovial; Soft tissue	20 mg/1mL
Injection, suspension	Intralesional; Intramuscular; Intrasynovial; Soft tissue	40 mg/1mL
Injection, suspension	Intralesional; Intramuscular; Intrasynovial; Soft tissue	80 mg/1mL
Suspension	Intra-articular; Intralesional; Intramuscular; Intrasynovial	20 mg
Suspension	Intra-articular; Intralesional; Intramuscular; Intrasynovial	80 mg
Suspension	Intra-articular; Intralesional; Intramuscular; Intrasynovial	40 mg
Solution	Intra-articular; Intrabursal
Kit	Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue; Subcutaneous; Topical
Kit	Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue; Topical
Gel	Topical	10 mg/1g
Kit	Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue
Kit		4 mg/1
Tablet	Oral	2 mg/1
Tablet	Oral	32 mg/1
Tablet	Oral	16 mg
Tablet	Oral	4 mg
Cream	Topical	2.5 mg
Tablet	Oral	16 mg/1
Tablet	Oral	4 mg/1
Tablet	Oral	8 mg/1
Injection, suspension	Intra-articular; Intralesional; Intramuscular; Parenteral; Soft tissue	40 mg/1mL
Injection, suspension	Intra-articular; Intralesional; Intramuscular; Parenteral; Soft tissue	80 mg/1mL
Injection, suspension	Intra-articular; Intralesional; Intramuscular; Soft tissue	40 mg/1mL
Injection, suspension	Intra-articular; Intralesional; Intramuscular; Soft tissue	80 mg/1mL
Injection, suspension	Intramuscular; Intrasynovial; Soft tissue	40 mg/1mL
Suspension	Intra-articular; Intramuscular; Intrasynovial; Soft tissue	40 mg
Suspension	Intra-articular; Intramuscular; Intrasynovial; Soft tissue	80 mg
Powder, for solution	Intramuscular; Intravenous	1 g
Powder, for solution	Intramuscular; Intravenous	125 mg
Powder, for solution	Intramuscular; Intravenous	40 mg
Powder, for solution	Intramuscular; Intravenous	5 g
Powder, for solution	Intramuscular; Intravenous	500 mg
Powder, for solution	Intramuscular; Intravenous
Kit	Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue; Topical
Cream	Topical
Lotion	Topical
Kit
Kit	Epidural; Infiltration; Intramuscular; Intrasynovial; Soft tissue; Topical
Kit	Infiltration; Soft tissue; Topical
Kit	Epidural; Infiltration; Intracaudal
Kit	Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue
Kit; powder	Intramuscular; Intravenous	1 g
Kit; powder	Intramuscular; Intravenous	125 mg
Kit; powder	Intramuscular; Intravenous	40 mg
Kit; powder	Intramuscular; Intravenous	500 mg
Kit; powder, for solution	Intramuscular; Intravenous	1 g
Kit; powder, for solution	Intramuscular; Intravenous	125 mg
Kit; powder, for solution	Intramuscular; Intravenous	40 mg
Kit; powder, for solution	Intramuscular; Intravenous	500 mg

Prices

Unit description	Cost	Unit
Methylprednisolone powder	96.25USD	g
Methylprednisolone ac powdr	40.09USD	g
Methylprednisolone ss 1 gm vial	31.2USD	vial
Solu-medrol 1 gm vial	24.43USD	vial
Solu-medrol (pf) 500 mg vial	20.9USD	vial
MethylPREDNISolone (Pak) 21 4 mg tablet Disp Pack	16.99USD	disp
Methylprednisolone 500 mg vial	15.6USD	vial
Solu-medrol 500 mg vial	12.9USD	vial
Depo-medrol 80 mg/ml vial	11.67USD	ml
Methylprednisolone 125 mg vial	10.0USD	vial
Methylprednisolone 80 mg/ml vial	9.12USD	ml
Depo-medrol 40 mg/ml vial	6.41USD	ml
Solu-medrol (pf) 125 mg vial	5.83USD	vial
Methylprednisolone 40 mg/ml vial	5.22USD	ml
Medrol 32 mg tablet	5.13USD	tablet
Methylprednisolone 32 mg tablet	4.62USD	tablet
Depo-medrol 20 mg/ml vial	3.78USD	ml
Methylprednisolone 16 mg tablet	3.17USD	tablet
Methylprednisolone 40 mg vial	3.0USD	vial
A-methapred 40 mg vial	2.36USD	vial
Medrol 16 mg tablet	2.28USD	tablet
Medrol 8 mg tablet	2.23USD	tablet
Methylprednisolone 8 mg tablet	1.74USD	tablet
Methylprednisolone 4 mg tablet	1.68USD	tablet
Medrol 4 mg dosepak	1.59USD	each
Medrol 4 mg tablet	0.99USD	tablet
Medrol 2 mg tablet	0.84USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	232.5 °C	PhysProp
water solubility	120 mg/L (at 25 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	1.5	Not Available
logS	-2.99	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.109 mg/mL	ALOGPS
logP	2.06	ALOGPS
logP	1.56	ChemAxon
logS	-3.5	ALOGPS
pKa (Strongest Acidic)	12.59	ChemAxon
pKa (Strongest Basic)	-2.9	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	94.83 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	103.04 m³·mol^-1	ChemAxon
Polarizability	40.77 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9911
Blood Brain Barrier	+	0.9484
Caco-2 permeable	-	0.6404
P-glycoprotein substrate	Substrate	0.7812
P-glycoprotein inhibitor I	Non-inhibitor	0.7489
P-glycoprotein inhibitor II	Non-inhibitor	0.604
Renal organic cation transporter	Non-inhibitor	0.769
CYP450 2C9 substrate	Non-substrate	0.8415
CYP450 2D6 substrate	Non-substrate	0.9115
CYP450 3A4 substrate	Substrate	0.7582
CYP450 1A2 substrate	Non-inhibitor	0.9473
CYP450 2C9 inhibitor	Non-inhibitor	0.907
CYP450 2D6 inhibitor	Non-inhibitor	0.9513
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Non-inhibitor	0.8309
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9167
Ames test	Non AMES toxic	0.9337
Carcinogenicity	Non-carcinogens	0.9529
Biodegradation	Not ready biodegradable	0.9492
Rat acute toxicity	2.0025 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9459
hERG inhibition (predictor II)	Non-inhibitor	0.5985

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a6r-0019000000-3a4955cf7cc34e1e8d0f
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0k9i-0696000000-003c4527b983cf71aefd
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-01p9-0980000000-e5097669b38e84057a0f
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-01p9-0960000000-ef914702163187cc80af
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-06y9-0940000000-54b01b6c04c68be3f1b3
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0009000000-3fe2869617af3697e2ed
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0009000000-8ad4f169606968256614
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0f79-0895000000-29d1cbf49bb2b32c5a98
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-01p9-0940000000-baa402ac94c228229ea2
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-01p9-0910000000-5cf9fb219d798a9316f4
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4r-0910000000-a2d2af7f573229dc3147
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0006-2900000000-a01d5bfe926dc48e6e4c
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0019000000-11519ee9583104c00505
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0gw0-0974000000-af5d4ebce055ce6efb23
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-01p9-0960000000-22e2342fcec2bf1cd833
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-01p9-0920000000-63759535c53af1efb13f
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0c09-1900000000-a48c07db31cf27cf0381
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-05tp-2900000000-b802f5e17b69cd6c707f
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0009000000-0e0cc8bfc7721357c5cf
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0bti-0896000000-86854a3fa2cb3c3bde0b
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4r-0796000000-b0070da713077c3f7975
MS/MS Spectrum - , positive	LC-MS/MS	splash10-01p9-3950000000-b938f656c358e1e42bb5

Taxonomy

Description: This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom: Organic compounds
Super Class: Lipids and lipid-like molecules
Class: Steroids and steroid derivatives
Sub Class: Hydroxysteroids
Direct Parent: 21-hydroxysteroids
Alternative Parents: Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols / Cyclic ketones
show 4 more
Substituents: Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid
show 15 more
Molecular Framework: Aliphatic homopolycyclic compounds
External Descriptors: 6-methylprednisolone (CHEBI:6888) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030178)

Targets

Details1. Glucocorticoid receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Agonist

General Function: Zinc ion binding
Specific Function: Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name: NR3C1
Uniprot ID: P04150
Uniprot Name: Glucocorticoid receptor
Molecular Weight: 85658.57 Da

References

Owen HC, Miner JN, Ahmed SF, Farquharson C: The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):164-70. Epub 2006 Dec 19. [PubMed:17182172]
Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM: Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl). 2006 Dec;189(2):225-35. Epub 2006 Oct 3. [PubMed:17016711]
Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY: Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G590-8. Epub 2006 Oct 26. [PubMed:17068119]
Quesnell RR, Han X, Schultz BD: Glucocorticoids stimulate ENaC upregulation in bovine mammary epithelium. Am J Physiol Cell Physiol. 2007 May;292(5):C1739-45. Epub 2007 Jan 24. [PubMed:17251323]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Details1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inducer

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Litt J. (2016). Litt's Drug eruption & reaction manual (22nd ed.). CRC Press LLc.

Transporters

Details1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Oka A, Oda M, Saitoh H, Nakayama A, Takada M, Aungst BJ: Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6. [PubMed:11913542]
Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]

Drug created on June 13, 2005 07:24 / Updated on December 18, 2018 05:46

Methylprednisolone

Identification

Structure for Methylprednisolone (DB00959)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

Enzymes

References

Transporters

References